Arnaud Autret
Angel Investor @ M Ventures
Paris, France
Arnaud Autret is a Series A investor at M Ventures in Paris focused on Biotechnology and Medical. Arnaud joined Seventure Partners Life Sciences team in January 2014.Previously, he worked for the Institut Pasteur and at Trinity College in Dublin as Head of R&D in Virology and Cancer.Prior to this, he worked as a Financial Auditor at KPMG Audit in the Healthcare sector for three years.Arnaud is a Doctor in Biology and Virologyfrom the Institut Pasteur. He has a Master’s Degree in Audit and Consulting from ESCP.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Arnaud Autret invests in
Stages Arnaud Autret invests in
Countries Arnaud Autret invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 1 (25%)
- Biopharma 1 (25%)
- Health Care 1 (25%)
- Therapeutics 1 (25%)
Stage
- Series A 2 (50%)
- Seed 1 (25%)
- Pre-Seed 1 (25%)
Country
- United Kingdom 2 (50%)
- France 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Broken String Biosciences is developing a platform of novel sequencing tools to assess genome stability and to unlock the next generation of innovative medicines, including cell and gene therapies. | $15M / Series A / Sep 18, 2023 | ||
| NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy. | $8.5M / Seed / Jul 19, 2021 | ||
| NanoSyrinx is an emerging biotechnology company developing a novel system for targeted delivery of therapeutic proteins and peptides direct to the cytosol. We are using synthetic biology approaches to develop a completely novel method for targeted drug delivery of therapeutic proteins and peptides, to the interiors of cells, to improve efficacy,safety, and economy. | Pre-Seed / Sep 30, 2020 | ||
| Scipio Bioscience, a Paris-based biotechnology company, provides a novel sample preparation solutionfor single-cell studies, in the form of benchtop kits, for use in sequencing applications in clinical and basic research, in particular transcriptomics. | $6.5M / Series A / Feb 25, 2020 |
Co-Investors
About M Ventures
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
M Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Christian Patze
Associate, Performance Materials
|
|||
Noga Yerushalmi
Head of Israel Bio-incubator
|
|||
Sarah Luppino
Associate
|
|||
Alexander Hoffmann
Principal
|
|||
Alicia Iruzun Lafitte
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Arnaud Autret invest in?
Arnaud Autret invests primarily in Biotechnology, Medical and Biopharma startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Arnaud Autret?
Public channels for Arnaud Autret include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Arnaud Autret last invest?
The most recent investment recorded for Arnaud Autret closed in Sep 2023. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
